Moreover, HDAC8-selective inhibition delayed neuroblastoma tumor growth more efficiently (BE(2)-C model; Figure 2d) or equally efficiently (IMR-32 model; Figure 2e) compared with vorinostat treatment. The gene discussed is HDAC8; the disease is neuroblastoma.